Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 20 for:    Pioneer III
Previous Study | Return to List | Next Study

PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03168776
Recruitment Status : Active, not recruiting
First Posted : May 30, 2017
Last Update Posted : July 23, 2020
Sponsor:
Collaborator:
Nova Vascular LLC
Information provided by (Responsible Party):
Sino Medical Sciences Technology Inc.

Tracking Information
First Submitted Date  ICMJE May 23, 2017
First Posted Date  ICMJE May 30, 2017
Last Update Posted Date July 23, 2020
Actual Study Start Date  ICMJE October 13, 2017
Estimated Primary Completion Date September 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 25, 2017)
Target lesion failure (TLF) [ Time Frame: 12 months ]
defined as the composite of cardiac death, target vessel related myocardial infarction (TV-MI), and clinically-driven target lesion revascularization (TLR)
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 25, 2017)
  • Long-term Safety and Efficacy defined as target lesion failure (TLF) between 12 months and 5 years by landmark analysis [ Time Frame: Between 12 months and 5 years ]
    TLF is defined as the composite of cardiac death, target vessel related myocardial infarction (TV-MI), and clinically-driven target lesion revascularization (TLR)
  • Major adverse cardiac events (MACE) [ Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years ]
    defined as a composite of all-cause death, myocardial infarction, and target vessel revascularization
  • Mortality [ Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years ]
    classified as cardiac or non-cardiac, and reported cumulatively and individually
  • Myocardial infarction (MI) [ Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years ]
    defined according to the modified Third Universal Definition
  • Stent thrombosis [ Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years ]
    definite or probable (ARC-defined), classified as early, late, or very late
  • Bleeding complications (BARC definitions) [ Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years ]
    evaluated as components and as a composite of BARC Type 3 and 5 bleeding
  • Lesion success [ Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years ]
    defined as attainment of <30% residual stenosis, as measured by quantitative coronary angiography (QCA) using any percutaneous method [evaluated post-procedure]
  • Device success [ Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years ]
    defined as attainment of <30% residual stenosis of the target lesion measured by QCA using the assigned device [evaluated post-procedure]
  • Procedure success [ Time Frame: 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years ]
    defined as lesion success without the occurrence of in-hospital MACE [evaluated in-hospital]
  • Clinically-driven target lesion revascularization (TLR) [ Time Frame: 30 days, 6 months, and 1, 2, 3, 4, and 5 years ]
    [evaluated in hospital and at 30 days, 6 months, and 1, 2, 3, 4 and 5 years]
  • Clinically-driven target vessel revascularization (TVR) [ Time Frame: 30 days, 6 months, and 1, 2, 3, 4, and 5 years ]
    [evaluated in hospital and at 30 days, 6 months, and 1, 2, 3, 4 and 5 years]
  • Target vessel failure (TVF) [ Time Frame: 30 days, 6 months, and 1, 2, 3, 4, and 5 years ]
    defined as cardiac death, target vessel-related MI, or clinically-driven target vessel revascularization [evaluated in hospital and at 30 days, 6 months, and 1, 2, 3, 4 and 5 years]
  • Target Lesion Failure (TLF) [ Time Frame: 30 days, 6 months, and 2, 3, 4, and 5 years ]
    defined as cardiac death, target vessel-related MI, or clinically-driven target lesion revascularization [evaluated in hospital and at 30 days, 6 months, and 2, 3, 4 and 5 years]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease
Official Title  ICMJE A Prospective Global Randomized Trial Assessing the Safety and Efficacy of the BuMA Supreme™ Biodegradable Drug Coated Coronary Stent System for Coronary Revascularization in Patients With Stable Coronary Artery Disease or Non-ST Segment Elevation Acute Coronary Syndromes
Brief Summary

The primary objective of this trial is to compare the safety and efficacy of the SINOMED BuMA Supreme biodegradable coronary stent in patients with up to 3 coronary lesions to either the XIENCE or Promus durable polymer coronary stents.

This prospective, global, multi-center, randomized 2:1, single blind study will enroll up to 1632 subjects at up to 130 investigational sites in North America, Japan, and Europe. Subjects will have clinical follow-up in-hospital and at 30 days, 6 months, 12 months, and 2, 3, 4, and 5 years.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Condition  ICMJE Coronary Artery Disease
Intervention  ICMJE
  • Device: BuMA Supreme DES
    Implant BuMA Supreme stent only
  • Device: Xience or Promus DES
    Implant XIENCE family or Promus family only
Study Arms  ICMJE
  • Experimental: BuMA Supreme Coronary Stent System
    Intervention: Device: BuMA Supreme DES
  • Active Comparator: Xience or Promus Everolimus Stent System
    Intervention: Device: Xience or Promus DES
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: May 25, 2017)
1632
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 2024
Estimated Primary Completion Date September 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. The patient is a male or non-pregnant female ≥20 years of age.
  2. The patient has symptomatic ischemic heart disease, including chronic stable angina (and/or objective evidence of myocardial ischemia on functional study or invasive fractional flow reserve [FFR] measurement) or acute coronary syndromes (UA or NSTEMI), that requires elective or urgent percutaneous coronary intervention (PCI).
  3. The patient is an acceptable candidate for percutaneous coronary intervention (PCI) with drug-eluting stents, and for emergent coronary bypass graft (CABG) surgery.
  4. The patient is willing to comply with specified follow-up evaluations.
  5. The patient or legally authorized representative has been informed of the nature of the study, agrees to its provisions, and has been provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).

Exclusion Criteria:

  1. Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure. Female patients of childbearing potential must have a negative pregnancy test done within 7 days prior to index procedure per site standard test.
  2. Patients with a history of bleeding diathesis or coagulopathy, contraindications to anti-platelet and/or anticoagulant therapy, or who will refuse transfusion.
  3. Patients who are receiving or will require chronic anticoagulation therapy for any reason.
  4. Known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, ADP receptor antagonists (clopidogrel, prasugrel, ticagrelor, ticlopidine), cobalt chromium, 316L stainless steel or platinum, sirolimus or its analogues, and/or contrast sensitivity that cannot be adequately pre-medicated.
  5. ST-segment elevation myocardial infarction (STEMI) at index presentation or within 7 days prior to randomization.
  6. Known LVEF <30% or cardiogenic shock requiring pressors or mechanical circulatory assistance (e.g., intra-aortic balloon pump, left ventricular assist device, other temporary cardiac support blood pump).
  7. Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease equation or Cockcroft-Gault formula) or dialysis at the time of screening.
  8. Target vessel percutaneous coronary intervention with stent placement in the previous 3 months.
  9. Planned elective surgery that would require discontinuation of DAPT within 6 months of the index procedure.
  10. Past or pending heart or any other organ transplant, or on the waiting list for any organ transplant.
  11. Patients who are receiving immunosuppressant therapy, or who have known immunosuppressive or severe autoimmune disease that will require chronic immunosuppressive therapy. NOTE: Corticosteroid use is permitted.
  12. Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol, confound data interpretation, or is associated with a life expectancy of less than 1 year.
  13. Current participation in another investigational drug or device study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 20 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   Canada,   Japan,   Netherlands,   Spain,   Switzerland,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03168776
Other Study ID Numbers  ICMJE SIN-US-001
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Sino Medical Sciences Technology Inc.
Study Sponsor  ICMJE Sino Medical Sciences Technology Inc.
Collaborators  ICMJE Nova Vascular LLC
Investigators  ICMJE
Study Chair: Martin B Leon, MD Center for Interventional Vascular Therapy - Columbia University Medical Center / New York-Presbyterian Hospital, United States
Principal Investigator: Dean Kereiakes, MD The Christ Hospital Physicians - Ohio Heart & Vascular, United States
Principal Investigator: Stephan Windecker, MD Bern University Hospital Department for Cardiology, Switzerland
Principal Investigator: Shigeru Saito, MD Shonan Kamakura General Hospital, Japan
PRS Account Sino Medical Sciences Technology Inc.
Verification Date August 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP